Our team of experienced researchers, nurses, study coordinators, and certified medical laboratory technicians create an environment of ethical and scientific standards that lead to our precision and reliable results.

With more than 400 trials completed since 1998, you can be assured that our conduct, quality control, recording, and reporting are done in a manner that protects the rights and safety of trial participants, while providing credible and accurate data.

As a consistent, and many times leading enroller, sponsors can rely on our recruitment efforts to provide the data that is needed, not only for entry, but for ongoing retention of records. Our patient care commitment is equally as strong as our commitment to data accuracy.

List of trials completed:

  • “Drug for the Treatment of Eyebrow Hypotrichosis.”
  • “A 52-Week, Phase III, Randomized, Double-Blind, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Drug, Followed by an Optional Long-Term Safety Extension Study, in Subjects with Moderate-to-Severe Chronic Plaque Psoriasis.”
  • “Drug Cream for the Treatment of Erythema Associated with Rosacea.”
  • “A Multicenter, Randomized, Double-Blind, Four-Week, Bilateral Study of the Safety and Efficacy of Two Concentrations of Drug Ointment Administered Once or Twice a Day in Adolescents with Atopic Dermatitis.”
  • “A Phase III Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Re-treatment with Drug in Subjects with Moderate to Severe Plaque Psoriasis.”
  • “A 12-Week Multicenter, Double-Blind, Randomized Withdrawal Extension Study of Subcutaneous Drug in Prefilled Syringes to Demonstrate Long-Term efficacy, Safety and Tolerability up to 2 Years in Subjects with Moderate to Severe Chronic Plaque-Type Psoriasis Completing Preceding Psoriasis Phase III Studies with Drug.”
  • “A Parallel-Group, Vehicle-Controlled, Randomized, Double-Blind Study of the Efficacy and Safety of Product Drug and Product Drug in Subjects with Seborrheic Dermatitis.”
  • “A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Drug to Drug and Placebo in Patients with Moderate to Severe Plaque Psoriasis with a Long-Term Extension Period.”
  • “A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Drug Cream, 3.75% to Drug Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp.”
  • “An Open-Label, Multicenter Study of the Efficacy of Drug Cream in the Treatment of Moderate Plaque Psoriasis for 28 Days.”
  • “Safety and Efficacy of Drug, 10% with Two dosing Regimens in Distal Subungual Onychomycosis of the Toenails: A Randomized, Double-Blind, Vehicle-controlled, Phase 2b/3 Study.”
  • “A Randomized, Double-Blind, Placebo Controlled, Multicenter Study of Subcutaneous Drug in Prefilled Syringes to Demonstrate Efficacy after Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-Term Efficacy in Subjects with Chronic Plaque-Type Psoriasis.”
  • “A Randomized, Phase II, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Drug Gel in Adult Patients with Mild to Moderate Atopic Dermatitis.”
  • “A Sequential Treatment Regimen of Cryotherapy and Drug Gel, 0.015% Field Therapy Compared to Cryotherapy Alone for the Treatment of Actinic Keratosis on the Face and Scalp.”
  • “A Phase 3b, Randomized, double-Blind, Active-Controlled, Multicenter Study to Evaluate a “Subject-Tailored” Maintenance dosing Approach in Subjects with Moderate-to-Severe Plaque Psoriasis.”
  • “A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of a Generic Drug Cream, 1% and Reference Listed Drug, 1% and Compare Both Active Treatments to a Vehicle Control in the Treatment of Interdigital Tinea Pedis.”
  • “A Phase II Study of Photodynamic Therapy with Drug Topical Solution verses Drug Enrolled 21 Topical Solution Vehicle-Blue Light Using Spot and Broad Area Application and Incubation times of 1,2 and 3 Hours for the Treatment of Multiple Actinic Keratoses on the Face or Scalp.”
  • “A Randomized, Double-Blind, Placebo Controlled, Multicenter Study of Subcutaneous Drug to Demonstrate Efficacy after Twelve Weeks of treatment, and to Assess the Safety, Tolerability and Long-Term Efficacy up to One Year in Subjects with Moderate to Severe Chronic Plaque-Type Psoriasis.”
  • “A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Evaluate the Safety and Efficacy of Drug Solution 0.03%, 0.1% and 0.3% Compared with Vehicle in Men with Androgenic Alopecia with an Open-Label Active Comparator Group.”
  • “A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Evaluate the Safety and Efficacy of Drug Solution 0.03%, 0.1% and 0.3% Compared with Vehicle in Women with Female Pattern Hair Loss with an Open-Label Active Comparator Group.”
  • “A Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of Rosacea-Related Inflammatory Biochemical Markers in the Skin of Adults with Papulopustular Rosacea Treated with Daily Drug Capsules.”
  • “A Multicenter, Randomized Double-Blind, Vehicle-Controlled, Parallel Group Study to Demonstrate the Efficacy and Assess the Safety of Drug Gel Applied Topically Once Daily in Subjects with Moderate to Severe Facial Erythema Associated with Rosacea.”
  • “A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Drug Purified Neurotoxin Complex in Subjects with Facial Rhytides (Crow’s Feet Lines and Glabellar Lines).”
  • “A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Drug Topical Solution vs. Solution Vehicle in the Treatment Onychomycosis of the Toenail in Adults.”
  • “A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of Generic Drug Cream and Drug Cream in Subjects with Actinic Keratoses.”
  • “A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Drug in Subjects with Moderate to Severe Plaque Psoriasis.”
  • “A Multicenter, Randomized, Double-Blind, 12-Week Study of the Safety and Efficacy of Drug vs. Drug Vehicle in the Treatment of Patients with Mild-to-Moderate Plaque-Type Psoriasis.”
  • “A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Drug in Subjects with Moderate to Severe Plaque Psoriasis.”
  • “Double-Blind, Randomized, Vehicle-Controlled, Multicenter, Multinational, Parallel-Group Study of the Efficacy and Safety of Drug Ointment in Concentrations of 0.01, 0.03 and 0.1% over 4 Weeks in Patients with Atopic Dermatitis (AD).”
  • “A Dose-Ranging and Efficacy Study of Drug (an Anti-IL-17 Antibody) in Patients with Moderate-to-Severe Psoriasis.”(Extension roll-over)
  • “A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety and Efficacy of Drug in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenails for 52 Weeks.”
  • “A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Drug Purified Neurotoxin Complex in Subjects with Facial Rhytides (Crow’s Feet Lines and Glabellar Lines).”
  • “A Pivotal USA Randomized, Evaluator-Blinded, Active-Controlled, Multi-Center, Split-Face Comparison Study of Drug vs. Drug in the Treatment of Moderate to Severe Facial Wrinkles and Folds.”
  • “A Multicenter, Randomized, Double-Blind Study of the Safety and Efficacy of Drug Foam vs. Vehicle Foam in the Treatment of Moderate Plaque-Type Scalp and Body Psoriasis.”
  • “A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study of the Clinical Activity, Safety, and Tolerability of Drug in subjects with Moderate to Severe Plaque-Type Psoriasis.”
  • “A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of Drug Foam vs. Drug Solution in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia).”
  • “A Dose-Ranging and Efficacy Study of Drug (an Anti-IL-17 Antibody) in Patients with Moderate-to-Severe Psoriasis.”
  • “A Randomized, Double-Blind, Vehicle- and Placebo-Controlled, Multicenter Trial in Patients with Mild to Moderate Distal Subungual Toenail Onychomycosis to Investigate the Efficacy, Tolerability and Safety of Twice Daily Application of Drug for 48 Weeks.”
  • “A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Drug, A Fully Human Anti-IL12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis.”
  • “An Evaluation of the Efficacy and Safety of Drug Emulsion Dressing in the Management of Signs and Symptoms of Mild to Moderate Atopic Dermatitis in Pediatric Subjects.”
  • “A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Drug, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis and Previously Treated with Biologic Anti-TNFα Agents.”
  • “A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of Drug in Subjects with Moderate to Severe Plaque Psoriasis.”
  • “A Phase 3, Multicenter, Randomized, Double-Blind Study Evaluating the Safety and Efficacy of Drug vs. Vehicle in Subjects with Mild to Moderate Onychomycosis of the Toenails.”
  • “A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Drug and Drug to Drug and Both Active Treatments to a Vehicle Control in the Treatment of Psoriasis Vulgaris.”
  • “A Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Drug Administered Subungually or Distally in the Treatment of Distal Subungual or Distally in the Treatment of Distal Subungual Onychomycosis of the Toenail.”
  • “A Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Drug in a Single Intravenous and a Single Subcutaneous Administration in Healthy Subjects and in Subjects with Moderate to Severe Psoriasis.”
  • “A 12 Month, Long-Term Follow-Up Study of Patients with Actinic Keratoses on the Head (Face or Scalp) Who Have Completed Day 57 in Studies A1 and A2.”
  • “A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study of the Dose-Response Profile of Drug Cream in Subjects with Erythematous Rosacea.”
  • “A Phase 2B, Multicenter, Treatment-Arm Blind, Safety and efficacy 28-Week Extension Study of Drug in Subjects who Completed the Treatment Phase of the Core Study.”
  • “Phase 1/2 Study Evaluating the Safety, Tolerability and Efficacy of Drug in Subjects with Atopic Dermatitis.”

And, more than 340 additional studies, including:

  • 98 Psoriasis
  • 31 Atopic Dermatitis
  • 22 Acne
  • 21 Actinic Keratoses
  • 20 HPA Axis
  • 7 Condyloma
  • 4 Carcinoma
  • 5 Seborrheic Dermatitis
  • 13 Rosacea
  • 5 Alopecia
  • 4 Tinea Versicolor
  • 4 SLE
  • 2 Warts
  • 2 Skin Aging
  • 7 Tinea Pedis
  • 5 Skin Infection
  • Venous Ulcers
  • Melasma
  • PMLE
  • Hyperhidrosis
  • CLE
  • Gout

Current trials, click here.